[1] Lu AYH. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos, 1998, 26(12): 1217-1222.
[2] Takahashi H, Wilkinson GRB, Nutescu EAC, Morita T, Ritchie MDE, Scordo MGF, Pengo V, Barban M, Padrini R, Ieiri I, Ostubo K, Kashima T, Kimura S, Kijima S, Echizen H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics, 2006, 16(2): 101-110.
[3] Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H. Population differences in S-warfarin metabolism between CYP2C9 geno-type-matched Caucasian and Japanese patients. Clin Pharmacol Ther, 2003, 73(3): 253-263.
[4] Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of aceno-coumarol sensitivity. Blood, 2005, 106(1): 135-140.
[5] Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996, 6(4): 341-349.
[6] Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet, 2005, 14(13): 1745-1751.
[7] Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Müller CR, Wienker TF, Oldenburg J. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost, 2005, 94(4): 773-779.
[8] 倪红兵, 鞠少卿, 王惠民. 焦磷酸测序技术及其应用进展. 国外医学临床生物化学与检验学分册, 2005, 26(9): 600-602.
[9] Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat, 2002, 19(5): 479-485.
[10] Okada Y, Nakamura K, Adachi A, Watai Y, Horiuchi R, Yamamoto K. Development of a single-tube PCR-pyrosequencing method for the simultaneous and rapid detection of four variant alleles of CYP2C9 gene polymorphism. J Clin Pharm Ther, 2008, 33(2): 187-192.
[11] 何震宇, 孙丽敏, 李月琴, 潘伟, 杨红. 广东人群CYP2C9等位基因及基因型分布频率. 广东医学, 2006, 27(8): 1131-1132.
[12] 马心超, 杨剑, 黄晨蓉, 缪丽燕. 江苏地区汉族人群中维生素K环氧化物还原酶亚单位1、细胞色素P4502C9的基因多态性. 苏州大学学报(医学版), 2009, 29(2): 279-282.
[13] Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and Patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005, 106(7): 2329-2333.
[14] Miao LY, Yang J, Huang CR, Shen ZY. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Phar-macol, 2007, 63(12): 1135-1141.
[15] Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RSJ, Voora D, Gatchel S, Tiemeier A, Gage BF. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood, 2007, 110(5): 1511-1515.
[16] Zhu YS, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem, 2007, 53(7): 1199-1205.
[17] 高菲, 宋洪涛, 曾志勇, 冯英力. CYP2C9和VKORC1基因多态性对心脏瓣膜置换术后华法林维持剂量和抗凝效果的影响. 中国药房, 2010, 21(22): 2053-2057.
[18] Lutter R, McWilliam A, Nardinelli C. Health care sa
